Why so many openings? Are the products doing that well to have expansions?
anonymous Guest anonymous   Dec 01, 2015 at 10:11: PM #1 anonymous Guest Why so many openings? Are the products doing that well to have expansions?
anonymous Guest anonymous   Dec 02, 2015 at 06:39: PM #2 anonymous Guest It's the Rituxan last hurrah push before patent expires in 2018 and the onsluaght of biosimilars by big and small pharmas. At least the jobs will last till 2018?
It's the Rituxan last hurrah push before patent expires in 2018 and the onsluaght of biosimilars by big and small pharmas. At least the jobs will last till 2018?
anonymous Guest anonymous   Dec 03, 2015 at 07:53: PM #3 anonymous Guest Pretty much what the above post says. Don't leave your current gig to come here. You may regret it later.
Pretty much what the above post says. Don't leave your current gig to come here. You may regret it later.